Baker BROS. Advisors LP Makes New Investment in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Posted by Brian Himes on Jun 18th, 2026

Baker BROS. Advisors LP purchased a new position in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 670,751 shares of the company’s stock, valued at approximately $16,775,000.

Several other institutional investors have also added to or reduced their stakes in CNTA. TD Waterhouse Canada Inc. acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $36,000. T. Rowe Price Investment Management Inc. boosted its holdings in Centessa Pharmaceuticals by 7,580.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after acquiring an additional 1,516 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after acquiring an additional 1,008 shares in the last quarter. Finally, Knott David M Jr acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth about $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Trading Up 0.3%

Shares of Centessa Pharmaceuticals stock opened at $39.87 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 9.53 and a quick ratio of 9.53. The firm has a fifty day moving average price of $39.65 and a 200 day moving average price of $31.11. Centessa Pharmaceuticals PLC Sponsored ADR has a 1 year low of $12.30 and a 1 year high of $40.26. The stock has a market cap of $6.17 billion, a PE ratio of -22.27 and a beta of 1.11.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Equities research analysts predict that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current year.

Insider Activity

In related news, insider Karen M. Anderson sold 41,076 shares of the firm’s stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the transaction, the insider owned 62,085 shares of the company’s stock, valued at $1,870,000.20. This trade represents a 39.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 4.09% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Wolfe Research downgraded Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a report on Tuesday, March 31st. Lifesci Capital lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 1st. Truist Financial lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 target price for the company. in a research note on Monday, April 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Monday, April 20th. Finally, Needham & Company LLC lowered Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Four equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Centessa Pharmaceuticals currently has an average rating of “Hold” and an average target price of $41.33.

Get Our Latest Stock Report on CNTA

About Centessa Pharmaceuticals

(Free Report)

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.